Alivus Life Sciences Limited ALIVUS.NS Open Alivus Life Sciences Limited in new tab
Alivus Life Sciences Limited Analysis (ALIVUS.NS)
Is Alivus Life Sciences Limited a good investment? Alivus Life Sciences Limited (ALIVUS.NS) is currently trading at 1060.80 INR. Market analysts have a consensus price target of 1158.33 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 23.92. This valuation is generally in line with the broader market.
Earnings Schedule: Alivus Life Sciences Limited is expected to release its next earnings report on July 31, 2026. The market consensus estimate for Forward EPS is 57.10.
For income investors, Alivus Life Sciences Limited pays a dividend yield of 0.47%. With a payout ratio of 11%, the dividend appears sustainable.
Investor FAQ
Does Alivus Life Sciences Limited pay a dividend?
Yes, it pays an annual dividend of 5.00 INR (0.47% yield).
What asset class is Alivus Life Sciences Limited?
Alivus Life Sciences Limited is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be July 31, 2026. The company currently has a trailing EPS of 44.27.
Company Profile
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Dividend Yield
0.47%
Annual Dividends
5.00 INR
Next ex. div date
Sept. 1, 2025
Payout Ratio
11.28%
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2026 | 5.00 INR |
| Sept. 14, 2026 (estimated) | 5.0000 |
| 2025 | 5.00 INR |
| Sept. 12, 2025 | 5.0000 |
| 2023 | 43.50 INR |
| Nov. 8, 2023 | 22.5000 |
| March 29, 2023 | 21.0000 |
| 2022 | 10.50 INR |
| Oct. 26, 2022 | 10.5000 |
| 2021 | 10.50 INR |
| Dec. 10, 2021 | 10.5000 |
Yearly aggregated dividends
Dividends
|
Alivus Life Sciences Limited
Sep 12, 2025 Paid
Dividend
5.0 INR |
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion